Fiscal Year End
The fund's objective is long-term capital appreciation.
To invest at least 80% of net assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.
Individuals seeking significant capital growth who can accept the risk of loss inherent in a fund that focuses on a volatile area of the market. Appropriate for both regular and tax-deferred accounts, such as IRAs.
Click on the risk/reward spectrum below to view the funds in that category
This fund offers the potential for long-term growth of capital by investing in companies engaged in the research, development, production, or distribution of health-related products or services. The health care field is experiencing unprecedented change, driven by attempts to hold down costs and by an aging population. Companies that can provide quality products at competitive prices should perform well. Technological breakthroughs in areas such as biotechnology can also lead to superior earnings growth.
Due to the fund's concentration in health sciences companies, its share price will be more volatile than that of more diversified funds. Further, these firms are often dependent on government funding and regulation and are vulnerable to product liability lawsuits and competition from low-cost generic products.